Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Gastrointestinal tumours, colorectal

400MO - Curative chemoradiation for low rectal cancer: Early clinical outcomes from a multicentre phase II trial

Date

18 Sep 2020

Session

Mini Oral - Gastrointestinal tumours, colorectal

Topics

Cytotoxic Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Lars Henrik Jensen

Citation

Annals of Oncology (2020) 31 (suppl_4): S409-S461. 10.1016/annonc/annonc270

Authors

L.H. Jensen1, L.Ø. Poulsen2, S.N. Risum3, J.D. Nielsen4, T. Mynster5, J. Ploeen1, H. Rahr1, B.M. Havelund1, A. Appelt1, J. Lindebjerg1, S.R. Rafaelsen1, A. Jakobsen1

Author affiliations

  • 1 Danish Colorectal Cancer Center South, University Hospital of Southern Denmark, 7100 - Vejle/DK
  • 2 Department Of Oncology, Aalborg University Hospital, 9000 - Aalborg/DK
  • 3 Department Of Oncology, University Hospital of Copenhagen, 2100 - Copenhagen/DK
  • 4 Department Of Surgery, Aalborg University Hospital, 9000 - Aalborg/DK
  • 5 Department Of Surgery, Bispebjerg Hospital and University Hospital of Copenhagen, 2100 - Copenhagen/DK

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 400MO

Background

Watchful waiting without surgery for rectal cancer is an option after complete response to chemoradiation. There is a need for optimising patient selection and radiotherapy to cure more patients with this modality. The aim of the study was to test high-dose radiotherapy of low rectal cancer for organ preservation in a multi-centre setting. The early endpoint of clinical complete response (cCR) at 12 weeks is reported here.

Methods

This prospective trial enrolled patients with rectal cancer 0-6 cm from the anal verge, T1-3 N0-1 M0, performance status 0-2, and adequate organ function. Radiotherapy consisted of 62 and 50.4 Gy to the tumour and regional lymph nodes, respectively, in 28 fractions using intensity-modulated radiation therapy and daily image guidance. Capecitabine 825mg/m2 BID was administered on treatment days. Patients with cCR 6-12 weeks from end of treatment judged by MRI, endoscopy, and digital rectal exam were referred to observation without surgery. The patients continue follow-up for recurrence, adverse events, and patient reported outcomes irrespective of treatment.

Results

Three Danish centres enrolled 108 patients from 9/2015 to 12/2019; with 15%/54%/31% T1/T2/T3 tumours; median tumour distance from anal verge 4.5 cm; 29% with N1 disease; 36% female; median age 71 years. 107 patients started treatment, the majority receiving full dose of radiotherapy (n=104) and of chemotherapy (n=80). The most frequent grade 3-4 toxicities were diarrhoea (7%), constipation (2%), and nausea, vomiting, pain, and skin reaction (all 1%). One patient died from other causes and one left the study before evaluation. 12 weeks after end of treatment, 13 patients had residual tumour and were referred for surgery; two had distant metastasis leaving 90 of 108 patients (83.3%) with cCR and allocation to follow-up without surgery.

Conclusions

The unprecedented high cCR rate of 83.3% in this multicentre phase II trial demonstrates that rectal cancer patients can be offered curative chemoradiation. Long-term outcomes, including tumour control, organ function, and quality of life, are still needed to evaluate the full potential of high-dose 62 Gy radiotherapy as a new standard treatment.

Clinical trial identification

NCT02438839.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Danish Cancer Society.

Disclosure

L.H. Jensen: Research grant/Funding (institution): MSD, InCyte, 2cureX, BMS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.